Should I buy or sell KALA BIO stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KALA BIO in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KALA shares. View KALA analyst ratings or view top-rated stocks .

What is KALA BIO's stock price target for 2024?

2 brokerages have issued 12-month price objectives for KALA BIO's shares. Their KALA share price targets range from $15.00 to $21.00. On average, they predict the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 173.1% from the stock's current price. View analysts price targets for KALA or view top-rated stocks among Wall Street analysts .

How have KALA shares performed in 2024?

KALA BIO's stock was trading at $7.00 at the beginning of the year. Since then, KALA shares have decreased by 5.9% and is now trading at $6.59. View the best growth stocks for 2024 here .

Are investors shorting KALA BIO?

KALA BIO saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 6,000 shares, a decrease of 50.4% from the March 15th total of 12,100 shares. Based on an average trading volume of 27,700 shares, the short-interest ratio is presently 0.2 days. Currently, 0.3% of the company's stock are sold short. View KALA BIO's Short Interest .

When is KALA BIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our KALA earnings forecast .

How were KALA BIO's earnings last quarter?

KALA BIO, Inc. (NASDAQ:KALA) released its earnings results on Monday, November, 15th. The company reported ($10.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($11.25) by $0.50. The firm earned $3.07 million during the quarter, compared to analyst estimates of $5.18 million. During the same period in the previous year, the business earned ($12.50) earnings per share.

When did KALA BIO's stock split?

Shares of KALA BIO reverse split on Friday, October 21st 2022. The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What is Mark Iwicki's approval rating as KALA BIO's CEO?

1 employees have rated KALA BIO Chief Executive Officer Mark Iwicki on Glassdoor.com . Mark Iwicki has an approval rating of 100% among the company's employees. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of KALA BIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other KALA BIO investors own include Pfizer (PFE) , Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , Micron Technology (MU) , Inovio Pharmaceuticals (INO) , VBI Vaccines (VBIV) , Amarin (AMRN) , Bristol-Myers Squibb (BMY) , NVIDIA (NVDA) and AbbVie (ABBV) .

When did KALA BIO IPO?

KALA BIO (KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

How do I buy shares of KALA BIO?

Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KALA

KALA BIO (KALA) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free KALA Stock Alerts

$6.33

-0.48 (-7.05%)

(As of 04/19/2024 ET)

Compare

Today's Range: $6.33
▼
$6.83
50-Day Range: $6.77
▼
$7.99
52-Week Range: $5.10
▼
$19.35

Volume: 7,568 shs
Average Volume: 26,468 shs
Market Capitalization: $17.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.00

Get KALA BIO alerts:

KALA BIO MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 173.1% Upside
$18.00 Price Target
Short Interest: Healthy
0.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.35
Upright™ Environmental Score
News Sentiment: -0.01
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($11.28) to ($11.50) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.91 out of 5 stars

Medical Sector

171st out of 918 stocks

Pharmaceutical Preparations Industry

63rd out of 417 stocks

3.5

Analyst's Opinion

Consensus Rating
KALA BIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
KALA BIO has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.25% of the float of KALA BIO has been sold short.
Short Interest Ratio / Days to Cover
KALA BIO has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in KALA BIO has recently decreased by 50.41%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
KALA BIO does not currently pay a dividend.
Dividend Growth
KALA BIO does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
KALA BIO has received a 66.18% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Glucocorticoids" and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for KALA BIO is -1.35.

1.7

News and Social Media Coverage

News Sentiment
KALA BIO has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for KALA BIO this week, compared to 1 article on an average week.
Search Interest
6 people have searched for KALA on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added KALA BIO to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, KALA BIO insiders have not sold or bought any company stock.
Percentage Held by Insiders
13.40% of the stock of KALA BIO is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 24.61% of the stock of KALA BIO is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for KALA BIO are expected to decrease in the coming year, from ($11.28) to ($11.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of KALA BIO is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of KALA BIO is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
KALA BIO has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About KALA BIO Stock (NASDAQ:KALA)

KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

KALA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KALA Stock News Headlines

April 18, 2024 | msn.com

Travis Kelce’s ex Kayla Nicole blasts Taylor Swift’s fans ahead of ‘TTPD’ album release: ‘Everyone has a breaking point’

April 16, 2024 | msn.com

Nicki Minaj Just Dropped a Sneaker Collection with This Low-Key Brand That Celebs Have Been Wearing for Years

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 13, 2024 | msn.com

What can you do with unwanted holy cards and Grandma’s religious statues?

April 12, 2024 | msn.com

Grace Charis' net worth and biography: Meet the TikTok golf star

April 11, 2024 | msn.com

Valerie Bertinelli, 63, Shares Stance on Ozempic and Trying to Lose ‘10 Pounds in a Week’

April 11, 2024 | msn.com

‘Shark Tank’ Star Barbara Corcoran Opens Up About Facelifts and Cosmetic Surgery

April 6, 2024 | ca.style.yahoo.com

I tried $1,441 worth of products from Sephora — here's what I'm re-buying (and skipping) from the spring sale

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 3, 2024 | msn.com

20 famous female celebrities struggling with hair loss

April 2, 2024 | ca.finance.yahoo.com

8 Former Child Stars Who've Moved On to 'Typical' (and Impressive!) Day Jobs

March 30, 2024 | msn.com

Makeup Artist Trinny Woodall, 60, Shares ‘Foolproof’ Spring Beauty Tips for All Ages

March 29, 2024 | finanznachrichten.de

KALA BIO, Inc.: KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 29, 2024 | globenewswire.com

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 28, 2024 | ca.style.yahoo.com

Amazon's Big Spring Sale is over, but these 40 extended deals are just as good — up to 73% off tech, home & more

March 28, 2024 | msn.com

Remembering the luminary: Here's how KPAC Sulochana and the golden years of theatre influenced Kerala

March 21, 2024 | msn.com

"All I See Are A Number Of Inaccurate Statements": 11 Celebrities Who Were Accused Of Lying About Their Background And Upbringing

March 18, 2024 | msn.com

Game of Thrones' Nathalie Emmanuel unveils short hair transformation

March 14, 2024 | msn.com

2024 NAACP Image Awards: The Complete Winners List

March 12, 2024 | msn.com

Denise Austin, 67, Demonstrates ‘Low-Impact’ Burpee in Latest Workout Video

February 26, 2024 | globenewswire.com

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

February 23, 2024 | benzinga.com

Kala Bio Stock (NASDAQ:KALA), Short Interest Report

February 22, 2024 | msn.com

First trailer for Outlander star Lauren Lyle's shark thriller

February 20, 2024 | msn.com

Here Are the Top 6 ‘Bachelor’ Contestants Still in the Running for Joey’s Heart

February 13, 2024 | msn.com

Patrick and Brittany Mahomes’ History With Travis Kelce’s Ex Kayla Nicole Explained

February 11, 2024 | msn.com

Travis Kelce's Ex Kayla Nicole Parties with Wives of San Francisco 49ers Players Ahead of 2024 Super Bowl

February 8, 2024 | msn.com

Sundance 2024 Slate Includes Films Starring Normani, André Holland, Mary J. Blige, Aunjanue Ellis-Taylor And More

See More Headlines

Receive KALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for KALA BIO and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KALA
CUSIP: N/A
CIK: 1479419
Web: www.kalarx.com
Phone: (781) 996-5252
Fax: 781-642-0399
Employees: 43
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.00
High Stock Price Target: $21.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +164.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($17.94)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,200,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -281.02%
Return on Assets: -65.57%

Debt

Debt-to-Equity Ratio: 5.10
Current Ratio: 6.33
Quick Ratio: 6.33

Sales & Book Value

Annual Sales: $3.89 million
Price / Sales: 4.93
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.79 per share
Price / Book: 2.44

Miscellaneous

Outstanding Shares: 2,820,000
Free Float: 2,439,000
Market Cap: $19.18 million
Optionable: Not Optionable
Beta: -1.85

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Mark T. Iwicki (Age 58)
Chairman & CEO
Comp: $1.1M
Mr. Todd Bazemore (Age 54)
President & COO
Comp: $783.04k
Dr. Kim Brazzell Ph.D. (Age 71)
Head of R&D and Chief Medical Officer
Comp: $750.91k
Dr. Justin Hanes Ph.D.
Founder & Chair of the Scientific Advisory Board
Ms. Mary Reumuth CPA (Age 49)
CFO & Treasurer
Ms. Jill S. Steier
Executive Director of Investor Relations & Corporate Communications
Mr. Eric L. Trachtenberg (Age 51)
Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Comp: $646.56k
Mr. Vincent Kosewski (Age 61)
Senior VP of Manufacturing & Supply Chain Management
Mr. Darius Kharabi J.D. (Age 44)
M.B.A., Chief Business Officer
Dr. Francis S. Mah M.D.
Chief Medical Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KALA Stock Analysis - Frequently Asked Questions

Should I buy or sell KALA BIO stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KALA BIO in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KALA shares.
View KALA analyst ratings or view top-rated stocks.
What is KALA BIO's stock price target for 2024?: 2 brokerages have issued 12-month price objectives for KALA BIO's shares. Their KALA share price targets range from $15.00 to $21.00. On average, they predict the company's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 173.1% from the stock's current price.
View analysts price targets for KALA or view top-rated stocks among Wall Street analysts.
How have KALA shares performed in 2024?: KALA BIO's stock was trading at $7.00 at the beginning of the year. Since then, KALA shares have decreased by 5.9% and is now trading at $6.59.
View the best growth stocks for 2024 here.
Are investors shorting KALA BIO?: KALA BIO saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 6,000 shares, a decrease of 50.4% from the March 15th total of 12,100 shares. Based on an average trading volume of 27,700 shares, the short-interest ratio is presently 0.2 days. Currently, 0.3% of the company's stock are sold short.
View KALA BIO's Short Interest.
When is KALA BIO's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our KALA earnings forecast.
How were KALA BIO's earnings last quarter?: KALA BIO, Inc. (NASDAQ:KALA) released its earnings results on Monday, November, 15th. The company reported ($10.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($11.25) by $0.50. The firm earned $3.07 million during the quarter, compared to analyst estimates of $5.18 million. During the same period in the previous year, the business earned ($12.50) earnings per share.

When did KALA BIO's stock split?: Shares of KALA BIO reverse split on Friday, October 21st 2022. The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
What is Mark Iwicki's approval rating as KALA BIO's CEO?: 1 employees have rated KALA BIO Chief Executive Officer Mark Iwicki on Glassdoor.com. Mark Iwicki has an approval rating of 100% among the company's employees. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of KALA BIO own?: Based on aggregate information from My MarketBeat watchlists, some companies that other KALA BIO investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Amarin (AMRN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA) and AbbVie (ABBV).
When did KALA BIO IPO?: KALA BIO (KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.
How do I buy shares of KALA BIO?: Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KALA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial